Browsing by Author "Bilgic, Basar"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Publication Multicenter study of levodopa carbidopa intestinal gel in parkinson's disease: The Turkish experience(Tubitak Scientific & Technological Research Council Turkey, 2020-01-01) Gultekin, Murat; Ulukan, Cagri; Tezcan, Sabiha; Dogu, Okan; Hanagasi, Hasmet; Bilgic, Basar; Bora Tokcaer, Ayse; Cakmur, Raif; Elibol, Bulent; Mirza, Meral; Ince Gunal, Dilek; Kenangil, Gulay; Yilmaz Kusbeci, Ozge; Akbostanci, Muhittin Cenk; Erer Ozbek, Cigdem Sevda; ERER ÖZBEK, ÇİĞDEM SEVDA; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.Background/aim: Our purpose was to determine the efficacy of levodopa carbidopa intestinal gel (LCIG) in a series of Turkish patients with Parkinson's disease (PD).Materials and methods: We had telephone calls with 54 patients from 11 neurology centers who were on LCIG treatment, and 44 patients or their caregivers were included in an eight-item survey between September 2015 and June 2016. The reliability and validity of the survey were evaluated with intraclass correlation coefficients for every question separately.Results: Average age of the patients were 63.48 and the duration of PD was 12.79 years. Average LCIG treatment period was 15.63 months. Percentages of the patients who reported they were 'better' after LCIG treatment were as follows: 80% for time spent off, 55% for dyskinesia, 65% for tremor, 85% for gait disorder, 50% for pain, 50% for sleep disorders, 42.5% for depression, 32.5% for incontinence, and 70% for activities of daily living. Cronbach's alpha was 0.795 and the intraclass correlation coefficient was reliable for the items.Conclusion: As detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG treatment in many aspects of the disease.Publication The distinct genetic pattern of als in turkey and novel mutations(Elsevier Science, 2015-04-01) Özoğuz, Aslıhan; Uyan, Özgün; Birdal, Güneş; İskender, Ceren; Kartal, Ece; Lahut, Suna; Ömür, Özgür; Ağım, Zeynep Sena; Eken, Aslı Gündoğdu; Sen, Nesli Ece; Kavak, Pınar; Saygi, Ceren; Sapp, Peter C.; Keagle, Pamela; Parman, Yesim; Tan, Ersin; Koc, Filiz; Deymeer, Feza; Oflazer, Piraye; Hanagasi, Hasmet; Gurvit, Hakan; Bilgic, Basar; Durmus, Hacer; Ertas, Mustafa; Kotan, Dilcan; Akalin, Mehmet Ali; Gulluoglu, Halil; Zarifoglu, Mehmet; Aysal, Fikret; Dosolu, Nilgun; Bilguvar, Kaya; Gunel, Murat; Keskin, Ozlem; Akgun, Tahsin; Ozcelik, Hilmi; Landers, John E.; Brown, Robert H.; Basak, A. Nazli; ZARİFOĞLU, MEHMET; Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.; EHN-5825-2022The frequency of amyotrophic lateral sclerosis (ALS) mutations has been extensively investigated in several populations; however, a systematic analysis in Turkish cases has not been reported so far. In this study, we screened 477 ALS patients for mutations, including 116 familial ALS patients from 82 families and 361 sporadic ALS (sALS) cases. Patients were genotyped for C9orf72 (18.3%), SOD1 (12.2%), FUS (5%), TARDBP (3.7%), and UBQLN2 (2.4%) gene mutations, which together account for approximately 40% of familial ALS in Turkey. No SOD1 mutations were detected in sALS patients; however, C9orf72 (3.1%) and UBQLN2 (0.6%) explained 3.7% of sALS in the population. Exome sequencing revealed mutations in OPTN, SPG11, DJ1, PLEKHG5, SYNE1, TRPM7, and SQSTM1 genes, many of them novel. The spectrum of mutations reflect both the distinct genetic background and the heterogeneous nature of the Turkish ALS population. (C) 2015 Elsevier Inc. All rights reserved.